BRIEF-Medincell Announces Initiation Of Phase 3 Study For Injectable Antipsychotic

* INITIATION OF THE PHASE 3 STUDY FOR THE SECOND LONG-ACTING
INJECTABLE ANTIPSYCHOTIC USING MEDINCELL’S TECHNOLOGY (PROGRAM
MDC-TJK)

* PHASE 3 STUDY CONDUCTED IN U.S. WILL ASSESS EFFICACY AND
SAFETY
OF FIRST SUBCUTANEOUS LONG-ACTING INJECTABLE (LAI) FORMULATION
OF OLANZAPINE FOR TREATMENT OF PATIENTS WITH SCHIZOPHRENIA

* ENROLLMENT OF FIRST PATIENTS IS EXPECTED IN COMING DAYS

* MDC-TJK FOLLOWS MDC-IRM (LAI RISPERIDONE), FIRST
SUBCUTANEOUS
ANTIPSYCHOTIC BASED ON MEDINCELL’S TECHNOLOGY CURRENTLY UNDER
REGULATORY REVIEW BY U.S. FDA, WITH A LAUNCH TARGET SET FOR H1
2023
Source text for Eikon:
Further company coverage:
(Reporting by Gdansk newsroom)


Read more here: Source link